Status:
COMPLETED
EXtension of Tablo TrEatmeNt Duration Registry
Lead Sponsor:
Outset Medical
Conditions:
End Stage Renal Disease (ESRD)
End Stage Renal Disease on Dialysis
Eligibility:
All Genders
Brief Summary
Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are ...
Eligibility Criteria
Inclusion
- Participant weighs ≥ 34kg.
- Participant is hospitalized and has dialysis dependent End-Stage Kidney Disease or Acute Kidney Injury and is prescribed renal replacement therapy \> 12 hours.
Exclusion
- Any documented condition that the Physician feels would prevent the participant from successful inclusion in the study.
Key Trial Info
Start Date :
May 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2022
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04912050
Start Date
May 25 2021
End Date
May 31 2022
Last Update
August 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Mark's Hospital
Salt Lake City, Utah, United States, 84124